World

i10 Productivity
Rankings

Eli Lilly and Company Scientists i10 Productivity Rankings 2024

Productivity Rankings is a unique service offered only by “AD Scientific Index”. This is a ranking system derived from the i10 index in order to show the productivity of the scientist in publishing scientific articles of value. Productivity Rankings is an instrument that lists productive scientists in a given area, discipline, university, and country and can guide the development of meaningful incentives and academic policies. The world rankings, regional rankings, and university rankings of scientists in this table are developed based on the total i10 index. Click for "last 6 years' i10 index". Also see: Universities Rankings 2024 (Sort by : Total i10 Index) and Universities Rankings 2024 (Sort by : Last 6 Years i10 Index)

Country Name

Total 240 scientist

List without CERN, Statistical Data etc

Sort by last 6 years i10 Index

David A Collier ⁱ

Best Scientist in University/Institution

Eli Lilly and Company

United States

Social Sciences / Psychology

psychosis

neurodegeneration

bioinformatics

genomics

drug development

i10 Productivity Rankings

University / Institution:

# 1

Country:

# 1,639

Region:

# 1,813

World:

# 4,872

i10 Index

Total:

441

Last 6 Year:

253

Last 6 Year/Total:

0.574

H-Index

Total:

124

Last 6 Year:

Last 6 Year/Total:

0.516

Citation

Total:

83,622

Last 6 Year:

29,380

Last 6 Year/Total:

0.351

Prachi Sharma ⁱ

Eli Lilly and Company

United States

Medical and Health Sciences / Immunology

Immuno-Oncology

i10 Productivity Rankings

University / Institution:

# 2

Country:

# 9,444

Region:

# 10,624

World:

# 28,190

i10 Index

Total:

211

Last 6 Year:

111

Last 6 Year/Total:

0.526

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.696

Citation

Total:

9,864

Last 6 Year:

5,383

Last 6 Year/Total:

0.546

Jiye Shi

Eli Lilly and Company

United States

Engineering & Technology / Nanoscience and Nanotechnology

Drug Discovery

Informatics

Computational Chemistry

Biophysics

Nanotechnology

i10 Productivity Rankings

University / Institution:

# 3

Country:

# 9,730

Region:

# 10,952

World:

# 29,133

i10 Index

Total:

207

Last 6 Year:

190

Last 6 Year/Total:

0.918

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.818

Citation

Total:

17,147

Last 6 Year:

11,542

Last 6 Year/Total:

0.673

Stephen Hall

Eli Lilly and Company

United States

Others

PBPK Models

DDI

CYPs

i10 Productivity Rankings

University / Institution:

# 4

Country:

# 13,733

Region:

# 15,503

World:

# 41,446

i10 Index

Total:

175

Last 6 Year:

106

Last 6 Year/Total:

0.606

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.468

Citation

Total:

22,740

Last 6 Year:

4,830

Last 6 Year/Total:

0.212

David R Ferry

Eli Lilly and Company

United States

Others

GI cancer

translational research

lung cancer

phase 1 trials

i10 Productivity Rankings

University / Institution:

# 5

Country:

# 13,761

Region:

# 15,532

World:

# 41,526

i10 Index

Total:

175

Last 6 Year:

Last 6 Year/Total:

0.486

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.548

Citation

Total:

26,553

Last 6 Year:

8,796

Last 6 Year/Total:

0.331

Tony Zhang

Eli Lilly and Company

United States

Natural Sciences / Chemical Sciences

process chemistry

organic chemistry. pharmaceutical

green chemistry

catalysis

i10 Productivity Rankings

University / Institution:

# 6

Country:

# 19,555

Region:

# 22,159

World:

# 60,657

i10 Index

Total:

143

Last 6 Year:

Last 6 Year/Total:

0.503

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.638

Citation

Total:

9,759

Last 6 Year:

4,183

Last 6 Year/Total:

0.429

Christian C Felder

Eli Lilly and Company

United States

Medical and Health Sciences / Neuroscience

Neuroscience & Drug Discovery

i10 Productivity Rankings

University / Institution:

# 7

Country:

# 19,981

Region:

# 22,654

World:

# 62,036

i10 Index

Total:

141

Last 6 Year:

Last 6 Year/Total:

0.610

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.447

Citation

Total:

25,108

Last 6 Year:

5,197

Last 6 Year/Total:

0.207

Jonathan A Lee

Eli Lilly and Company

United States

Others

i10 Productivity Rankings

University / Institution:

# 8

Country:

# 20,564

Region:

# 23,330

World:

# 63,954

i10 Index

Total:

139

Last 6 Year:

Last 6 Year/Total:

0.237

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.396

Citation

Total:

9,826

Last 6 Year:

2,531

Last 6 Year/Total:

0.258

Michael O'Neill

Eli Lilly and Company

United States

Others

Neurodegeneration

Neuroscience

i10 Productivity Rankings

University / Institution:

# 9

Country:

# 21,441

Region:

# 24,346

World:

# 67,027

i10 Index

Total:

135

Last 6 Year:

Last 6 Year/Total:

0.556

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.525

Citation

Total:

10,973

Last 6 Year:

3,769

Last 6 Year/Total:

0.343

Bob Campbell

Eli Lilly and Company

United States

Medical and Health Sciences / Medical Oncology

oncology/I-O/autoimmune diseases

drug discovery

kinases

epigenetics

RNA modulation

i10 Productivity Rankings

University / Institution:

# 10

Country:

# 28,688

Region:

# 32,641

World:

# 92,148

i10 Index

Total:

112

Last 6 Year:

Last 6 Year/Total:

0.366

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.491

Citation

Total:

9,902

Last 6 Year:

3,341

Last 6 Year/Total:

0.337

Click for INSTITUTIONAL BULK REGISTRATION and PREMIUM MEMBERSHIP advantages

Eswar Krishnan

Eli Lilly and Company

United States

Others

i10 Productivity Rankings

University / Institution:

# 11

Country:

# 31,230

Region:

# 35,549

World:

# 101,211

i10 Index

Total:

105

Last 6 Year:

Last 6 Year/Total:

0.829

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.629

Citation

Total:

12,881

Last 6 Year:

4,962

Last 6 Year/Total:

0.385

José Antonio Sacristán

Eli Lilly and Company

United States

Others

Clinical research

patients

methodology

effectiveness

cost-effectiveness

i10 Productivity Rankings

University / Institution:

# 12

Country:

# 32,331

Region:

# 36,855

World:

# 105,358

i10 Index

Total:

103

Last 6 Year:

Last 6 Year/Total:

0.388

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.500

Citation

Total:

6,599

Last 6 Year:

2,299

Last 6 Year/Total:

0.348

JH Krege

Eli Lilly and Company

United States

Others

Osteoporosis

Migraine

Cardiovascular Disease

Drug Development

i10 Productivity Rankings

University / Institution:

# 13

Country:

# 34,390

Region:

# 39,255

World:

# 112,807

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.755

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.636

Citation

Total:

14,877

Last 6 Year:

3,829

Last 6 Year/Total:

0.257

David H Adams

Eli Lilly and Company

United States

Others

i10 Productivity Rankings

University / Institution:

# 14

Country:

# 39,986

Region:

# 45,617

World:

# 132,912

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.591

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.659

Citation

Total:

8,559

Last 6 Year:

3,909

Last 6 Year/Total:

0.457

Imre Pavo

Eli Lilly and Company

United States

Others

diabetes

cardiovascular diseases

osteoporosis

i10 Productivity Rankings

University / Institution:

# 15

Country:

# 41,182

Region:

# 46,978

World:

# 137,469

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.605

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.641

Citation

Total:

5,680

Last 6 Year:

2,352

Last 6 Year/Total:

0.414

Stéphane Epelbaum

Eli Lilly and Company

United States

Medical and Health Sciences / Neuroscience

Alzheimer's disease

i10 Productivity Rankings

University / Institution:

# 16

Country:

# 42,683

Region:

# 48,722

World:

# 143,055

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.964

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.947

Citation

Total:

11,046

Last 6 Year:

8,340

Last 6 Year/Total:

0.755

Martin Citron

Eli Lilly and Company

United States

Others

Alzheimer's disease

Neurodegeneration

Drug discovery

i10 Productivity Rankings

University / Institution:

# 17

Country:

# 44,240

Region:

# 50,497

World:

# 148,841

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.753

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.627

Citation

Total:

35,882

Last 6 Year:

6,305

Last 6 Year/Total:

0.176

Francis Willard

Eli Lilly and Company

United States

Medical and Health Sciences / Pharmacology

Drug Discovery

G-proteins

GPCRs

Receptors

Pharmacology

i10 Productivity Rankings

University / Institution:

# 18

Country:

# 44,357

Region:

# 50,633

World:

# 149,291

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.654

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.583

Citation

Total:

7,859

Last 6 Year:

2,696

Last 6 Year/Total:

0.343

Giacomo Ruotolo

Eli Lilly and Company

United States

Others

Lipoprotein Metabolism and Atherosclerosis

i10 Productivity Rankings

University / Institution:

# 19

Country:

# 49,514

Region:

# 56,552

World:

# 168,908

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.622

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.628

Citation

Total:

7,651

Last 6 Year:

2,573

Last 6 Year/Total:

0.336

Mark L Hartman

Eli Lilly and Company

United States

Medical and Health Sciences / Endocrinology and Metabolism

Diabetes

endocrinology

fatty liver disease

i10 Productivity Rankings

University / Institution:

# 20

Country:

# 49,611

Region:

# 56,662

World:

# 169,319

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.527

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.431

Citation

Total:

9,920

Last 6 Year:

1,996

Last 6 Year/Total:

0.201

Scot J Matkovich

Eli Lilly and Company

United States

Others

Heart disease

inflammation

diabetes

noncoding RNAs

systems biology

i10 Productivity Rankings

University / Institution:

# 21

Country:

# 50,125

Region:

# 57,246

World:

# 171,254

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.781

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.727

Citation

Total:

7,409

Last 6 Year:

2,932

Last 6 Year/Total:

0.396

Joel Raskin

Eli Lilly and Company

United States

Social Sciences / Psychology

psychopharmamcology

i10 Productivity Rankings

University / Institution:

# 22

Country:

# 51,217

Region:

# 58,497

World:

# 175,503

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.569

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.548

Citation

Total:

7,270

Last 6 Year:

2,340

Last 6 Year/Total:

0.322

Howard Broughton

Eli Lilly and Company

United States

Natural Sciences / Chemical Sciences

Computational chemistry

molecular modeling

biophysics

i10 Productivity Rankings

University / Institution:

# 23

Country:

# 51,409

Region:

# 58,705

World:

# 176,294

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.306

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.469

Citation

Total:

4,115

Last 6 Year:

757

Last 6 Year/Total:

0.184

Joe Johnston

Eli Lilly and Company

United States

Medical and Health Sciences / Pediatrics and Child Health

Health outcomes

pediatrics

epidemiology

i10 Productivity Rankings

University / Institution:

# 24

Country:

# 55,689

Region:

# 63,552

World:

# 192,412

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.612

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.618

Citation

Total:

7,058

Last 6 Year:

3,140

Last 6 Year/Total:

0.445

Richard E Higgs

Eli Lilly and Company

United States

Natural Sciences / Mathematical Sciences

Statistics

Applied statistics in drug discovery

Translational research

i10 Productivity Rankings

University / Institution:

# 25

Country:

# 55,756

Region:

# 63,630

World:

# 192,704

i10 Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.552

H-Index

Total:

Last 6 Year:

Last 6 Year/Total:

0.590

Citation

Total:

7,814

Last 6 Year:

4,650

Last 6 Year/Total:

0.595

				AD Scientific Index - World Scientists i10 Productivity Rankings - 2024				i10 INDEX			H INDEX			CITATION
University	Country	Region	World	Name	Country	University / Institution	Subject	Total	Last 6 Year	Last 6 year/total	Total	Last 6 year	Last 6 year/total	Total	Last 6 year	Last 6 year/total
1	1,639	1,813	4,872	David A Collier ⁱ	United States	Eli Lilly and Company	Social Sciences / Psychology psychosis \| neurodegeneration \| bioinformatics \| genomics \| drug development \|	441	253	0.574	124	64	0.516	83,622	29,380	0.351
2	9,444	10,624	28,190	Prachi Sharma ⁱ	United States	Eli Lilly and Company	Medical and Health Sciences / Immunology Immuno-Oncology \|	211	111	0.526	46	32	0.696	9,864	5,383	0.546
3	9,730	10,952	29,133	Jiye Shi	United States	Eli Lilly and Company	Engineering & Technology / Nanoscience and Nanotechnology Drug Discovery \| Informatics \| Computational Chemistry \| Biophysics \| Nanotechnology \|	207	190	0.918	66	54	0.818	17,147	11,542	0.673
4	13,733	15,503	41,446	Stephen Hall	United States	Eli Lilly and Company	Others PBPK Models \| DDI \| CYPs \|	175	106	0.606	77	36	0.468	22,740	4,830	0.212
5	13,761	15,532	41,526	David R Ferry	United States	Eli Lilly and Company	Others GI cancer \| translational research \| lung cancer \| phase 1 trials \|	175	85	0.486	73	40	0.548	26,553	8,796	0.331
6	19,555	22,159	60,657	Tony Zhang	United States	Eli Lilly and Company	Natural Sciences / Chemical Sciences process chemistry \| organic chemistry. pharmaceutical \| green chemistry \| catalysis \|	143	72	0.503	47	30	0.638	9,759	4,183	0.429
7	19,981	22,654	62,036	Christian C Felder	United States	Eli Lilly and Company	Medical and Health Sciences / Neuroscience Neuroscience & Drug Discovery \|	141	86	0.610	76	34	0.447	25,108	5,197	0.207
8	20,564	23,330	63,954	Jonathan A Lee	United States	Eli Lilly and Company	Others	139	33	0.237	48	19	0.396	9,826	2,531	0.258
9	21,441	24,346	67,027	Michael O'Neill	United States	Eli Lilly and Company	Others Neurodegeneration \| Neuroscience \|	135	75	0.556	61	32	0.525	10,973	3,769	0.343
10	28,688	32,641	92,148	Bob Campbell	United States	Eli Lilly and Company	Medical and Health Sciences / Medical Oncology oncology/I-O/autoimmune diseases \| drug discovery \| kinases \| epigenetics \| RNA modulation \|	112	41	0.366	53	26	0.491	9,902	3,341	0.337
			Click for INSTITUTIONAL BULK REGISTRATION and PREMIUM MEMBERSHIP advantages
11	31,230	35,549	101,211	Eswar Krishnan	United States	Eli Lilly and Company	Others	105	87	0.829	62	39	0.629	12,881	4,962	0.385
12	32,331	36,855	105,358	José Antonio Sacristán	United States	Eli Lilly and Company	Others Clinical research \| patients \| methodology \| effectiveness \| cost-effectiveness \|	103	40	0.388	40	20	0.500	6,599	2,299	0.348
13	34,390	39,255	112,807	JH Krege	United States	Eli Lilly and Company	Others Osteoporosis \| Migraine \| Cardiovascular Disease \| Drug Development \|	98	74	0.755	55	35	0.636	14,877	3,829	0.257
14	39,986	45,617	132,912	David H Adams	United States	Eli Lilly and Company	Others	88	52	0.591	41	27	0.659	8,559	3,909	0.457
15	41,182	46,978	137,469	Imre Pavo	United States	Eli Lilly and Company	Others diabetes \| cardiovascular diseases \| osteoporosis \|	86	52	0.605	39	25	0.641	5,680	2,352	0.414
16	42,683	48,722	143,055	Stéphane Epelbaum	United States	Eli Lilly and Company	Medical and Health Sciences / Neuroscience Alzheimer's disease \|	83	80	0.964	38	36	0.947	11,046	8,340	0.755
17	44,240	50,497	148,841	Martin Citron	United States	Eli Lilly and Company	Others Alzheimer's disease \| Neurodegeneration \| Drug discovery \|	81	61	0.753	59	37	0.627	35,882	6,305	0.176
18	44,357	50,633	149,291	Francis Willard	United States	Eli Lilly and Company	Medical and Health Sciences / Pharmacology Drug Discovery \| G-proteins \| GPCRs \| Receptors \| Pharmacology \|	81	53	0.654	48	28	0.583	7,859	2,696	0.343
19	49,514	56,552	168,908	Giacomo Ruotolo	United States	Eli Lilly and Company	Others Lipoprotein Metabolism and Atherosclerosis \|	74	46	0.622	43	27	0.628	7,651	2,573	0.336
20	49,611	56,662	169,319	Mark L Hartman	United States	Eli Lilly and Company	Medical and Health Sciences / Endocrinology and Metabolism Diabetes \| endocrinology \| fatty liver disease \|	74	39	0.527	51	22	0.431	9,920	1,996	0.201
21	50,125	57,246	171,254	Scot J Matkovich	United States	Eli Lilly and Company	Others Heart disease \| inflammation \| diabetes \| noncoding RNAs \| systems biology \|	73	57	0.781	44	32	0.727	7,409	2,932	0.396
22	51,217	58,497	175,503	Joel Raskin	United States	Eli Lilly and Company	Social Sciences / Psychology psychopharmamcology \|	72	41	0.569	42	23	0.548	7,270	2,340	0.322
23	51,409	58,705	176,294	Howard Broughton	United States	Eli Lilly and Company	Natural Sciences / Chemical Sciences Computational chemistry \| molecular modeling \| biophysics \|	72	22	0.306	32	15	0.469	4,115	757	0.184
24	55,689	63,552	192,412	Joe Johnston	United States	Eli Lilly and Company	Medical and Health Sciences / Pediatrics and Child Health Health outcomes \| pediatrics \| epidemiology \|	67	41	0.612	34	21	0.618	7,058	3,140	0.445
25	55,756	63,630	192,704	Richard E Higgs	United States	Eli Lilly and Company	Natural Sciences / Mathematical Sciences Statistics \| Applied statistics in drug discovery \| Translational research \|	67	37	0.552	39	23	0.590	7,814	4,650	0.595